Literature DB >> 22556352

Nuclear factor-κB dysregulation in splenic marginal zone lymphoma: new therapeutic opportunities.

Luca Arcaini, Davide Rossi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22556352      PMCID： PMC3342963          DOI： 10.3324/haematol.2011.058362

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  28 in total

1.  Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma.

Authors:  Luca Arcaini; Ester Orlandi; Monica Scotti; Ercole Brusamolino; Francesco Passamonti; Sara Burcheri; Nora Colombo; Laura Vanelli; Giovanni Sbalzarini; Mario Lazzarino
Journal:  Clin Lymphoma       Date:  2004-03

2.  Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

Authors:  Owen A O'Connor; John Wright; Craig Moskowitz; Jamie Muzzy; Barbara MacGregor-Cortelli; Michael Stubblefield; David Straus; Carol Portlock; Paul Hamlin; Elizabeth Choi; Otila Dumetrescu; Dixie Esseltine; Elizabeth Trehu; Julian Adams; David Schenkein; Andrew D Zelenetz
Journal:  J Clin Oncol       Date:  2004-12-21       Impact factor: 44.544

3.  Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes.

Authors:  Emilio Iannitto; Viviana Minardi; Giuseppina Calvaruso; Emanuele Ammatuna; Ada Maria Florena; Antonino Mulè; Claudio Tripodo; Gerlando Quintini; Vincenzo Abbadessa
Journal:  Eur J Haematol       Date:  2005-08       Impact factor: 2.997

4.  BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas.

Authors:  Qingguo Yan; Yuanxue Huang; A James Watkins; Sylvia Kocialkowski; Naiyan Zeng; Rifat A Hamoudi; Peter G Isaacson; Laurence de Leval; Andrew Wotherspoon; Ming-Qing Du
Journal:  Haematologica       Date:  2011-11-18       Impact factor: 9.941

5.  Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes.

Authors:  F Lefrère; O Hermine; C Belanger; S François; H Tilly; J C Lebas de La Cour; F Valensi; B Varet; X Troussard
Journal:  Leukemia       Date:  2000-04       Impact factor: 11.528

6.  Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients.

Authors:  Jose I Chacón; Manuela Mollejo; Enriqueta Muñoz; Patricia Algara; Marisol Mateo; Luis Lopez; Jesús Andrade; Iciar García Carbonero; Beatriz Martínez; Miguel A Piris; Miguel A Cruz
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

Review 7.  Splenic marginal-zone lymphoma: a distinct clinical and pathological entity.

Authors:  Catherine Thieblemont; Pascale Felman; Evelyne Callet-Bauchu; Alexandra Traverse-Glehen; Gilles Salles; Françoise Berger; Bertrand Coiffier
Journal:  Lancet Oncol       Date:  2003-02       Impact factor: 41.316

8.  Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity?

Authors:  David Saadoun; Felipe Suarez; François Lefrere; Françoise Valensi; Xavier Mariette; Achille Aouba; Caroline Besson; Bruno Varet; Xavier Troussard; Patrice Cacoub; Oliver Hermine
Journal:  Blood       Date:  2004-09-07       Impact factor: 22.113

9.  Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas.

Authors:  C Kelaidi; F Rollot; S Park; M Tulliez; B Christoforov; Y Calmus; P Podevin; D Bouscary; P Sogni; P Blanche; F Dreyfus
Journal:  Leukemia       Date:  2004-10       Impact factor: 11.528

10.  Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection.

Authors:  Olivier Hermine; François Lefrère; Jean-Pierre Bronowicki; Xavier Mariette; Katayoun Jondeau; Virginie Eclache-Saudreau; Béatrice Delmas; Françoise Valensi; Patrice Cacoub; Christian Brechot; Bruno Varet; Xavier Troussard
Journal:  N Engl J Med       Date:  2002-07-11       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.